The name OrsoBio is inspired by the remarkable metabolic adaptability of bears (“orso” in Italian) that enables them to avoid serious sequelae despite extreme environmental challenges before and during hibernation, including absence of food, cold temperatures, and immobilization. In this context, OrsoBio is dedicated to developing therapies that restore energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant to maintaining energy balance in the healthy bear.
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
